Navigation Links
Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
Date:10/25/2010

d in patients not on dialysis, and how those results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) in patients with chronic kidney disease (CKD).  The Company will continue to work with the FDA to develop information that will optimize the use of ESAs in CKD patients.

Denosumab:  The Company reaffirmed that the Prescription Drug User Fee Act (PDUFA) action date for its application for denosumab for the treatment of bone metastases to reduce skeletal related events in patients with cancer is Thursday, Nov. 18, 2010.  The FDA granted priority review designation to denosumab for this indication. Priority review designation is granted to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists.

The Company reaffirmed that data from study ‘147 for denosumab in the prevention of prostate cancer bone metastases is expected to be available in the fourth quarter of 2010.  

Vectibix:  The Company announced that it plans to file supplemental Biologics License Applications for first- and second-line metastatic colorectal cancer indications in the U.S. during the fourth quarter of 2010.

Non-GAAP Financial MeasuresManagement has presented its operating results in accordance with GAAP and on an “adjusted” (or non-GAAP basis) for the three and nine months ended Sept. 30, 2010 and 2009. In addition, management has presented its outstanding debt in accordance with GAAP and on an “adjusted” (or non-GAAP basis) as of Sept. 30, 2010.  The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors.  The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning.  These non-GAAP financial measures are in addition to, not a substitute for, or superior to, m
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. NCPA Digest Finds Independent Community Pharmacies Stable Despite Economic, Third-Party Challenges
2. WuXi PharmaTech Schedules Third-Quarter 2010 Earnings Conference Call
3. Roper Industries Announces Record Third Quarter Results
4. Sinovac Announces Preliminary Unaudited Third Quarter 2010 Sales Range and Revises Full Year 2010 Sales Expectations
5. China Medicine to Announce Third Quarter 2010 Financial Results on November 10, 2010
6. Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results
7. Thoratec Schedules Third Quarter Conference Call, Webcast
8. Essilor - Third-Quarter 2010 Report
9. CVS Caremark Corporation to Hold Third Quarter 2010 Conference Call
10. VirtualScopics Schedules Third Quarter 2010 Earnings Announcement
11. Danaher Reports Record Third Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014 Zynerba Pharmaceuticals , Inc., a ... transdermal synthetic cannabinoid treatments, today announced that the company ... Conference 2014. The conference will be held December 2 ... New York . Zynerba,s Chairman and CEO, ... on Tuesday, December 2. To listen to ...
(Date:11/26/2014)... WASHINGTON and NEW YORK ... 2014 As the leading distributor of market ... a new research report by IQ4I Research and Consultancy ... To learn more about IQ4I Research visit: ... Active Pharmaceutical Ingredients Global Market – Forecast ...
(Date:11/26/2014)... , Nov. 25, 2014 Reinforcing its ... Philips (NYSE: PHG AEX: PHIA) ... Drug Administration (FDA) for its IQon Spectral CT ... This first-of-its kind technology adds a new dimension to ... the ability to characterize structures based on their material ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3
... Water Street Healthcare Partners , a strategic ... today that it has acquired MarketLab, Inc. ... in the specialty healthcare distribution sector.  The acquisition expands ... in distribution, life sciences, medical devices and services to ...
... Colo., June 27, 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: ... "Company"), a company that discovers and develops new uses ... today announced results of its phase III, randomized, double-blind, ... of two doses of Zertane™ for the treatment of ...
Cached Medicine Technology:Water Street Healthcare Partners Acquires MarketLab, Inc. 2Water Street Healthcare Partners Acquires MarketLab, Inc. 3Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 2Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 3Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 4Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction 5
(Date:11/27/2014)... York, New York (PRWEB) November 27, 2014 ... ) have been filed in a consolidated ... Liebhard LLP reports. , Documents recently updated ... 1,079 records included in the state proceeding, all ... schizophrenia, bipolar disorder and other psychiatric conditions. Many ...
(Date:11/27/2014)... Most babies and young children don,t need medicines if ... Administration says. Over-the-counter (OTC) cold and cough medicine ... because they could cause serious and potentially deadly side ... three colds a year, but children get them more ... to give them pain relievers, decongestants and other medicines, ...
(Date:11/27/2014)... meals can pose a challenge for people who have ... Many traditional Thanksgiving dishes -- such as turkey, corn, ... "when it comes to pies, stuffing, gravy, etc., gluten-free ... director of the Gluten and Allergic Digestive Disorders program ... said in a center news release. "For those ...
(Date:11/27/2014)... The founders of VIM & VIGR, a company ... compression socks, are proud to announce the debut of their ... Pressure (TM) knitting technology that is designed to increase the ... to adding flair and style to a product that has ... eye of a writer at The New York Times ...
(Date:11/27/2014)... Now that Thanksgiving is finally here ... Emassagechair.com has announced its eagerly awaited, once ... , Negotiating on behalf of their customers, and drawing ... Emassagechair.com has generated significant buzz in the industry with ... yet. , Shoppers are excited for significant savings available ...
Breaking Medicine News(10 mins):Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 2Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 3Health News:New Risperdal Lawsuits Added to Philadelphia Litigation, Bernstein Liebhard LLP Reports 4Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:VIM & VIGR Announces Launch of Men’s Line of Compression Socks 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4
... News) -- Statins, a class of cholesterol-lowering drugs that includes ... had a certain kind of stroke with unknown cause, a ... young people, and it,s even more uncommon for them to ... the Aug. 2 issue of the journal Neurology , ...
... fecal occult blood test (iFOBT) is effective for predicting ... upper gastrointestinal (GI) tract, confirms a study in ... link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . The immunochemical fecal ... screen for bleeding without symptoms in the lower GI ...
... of 1 percent of the microbes that live in the colon, ... gut are fundamental to colon health. In a new study ... where they live and how abundant they are in different parts ... International Society for Microbial Ecology Journal . This is ...
... A novel therapy that reduces elevated blood levels of a ... of pregnancy, may someday address the therapeutic dilemma posed by ... the dangers that early delivery poses to an immature fetus. ... Circulation , a team of U.S. and German researchers ...
... a lower socioeconomic status neighborhood are more likely to ... more affluent neighborhoods, according to a new RAND Corporation study. ... of Public Health , is the largest of its type ... with lower cognitive function. The study found that potential ...
... of Vanderbilt University was awarded a $25,000 grant from ... research in abnormal BCL6 overexpression, which occurs in a ... Vanderbilt University have obtained drugs that inhibit HDAC3another epigenetic ... cancer. Scientists believe that by eliminating BCL6, they can ...
Cached Medicine News:Health News:Statins May Help Heart in Some Young Stroke Patients 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Researchers map minority microbes in the colon 2Health News:Researchers map minority microbes in the colon 3Health News:Pilot study suggests new approach to treat preeclampsia 2Health News:Pilot study suggests new approach to treat preeclampsia 3Health News:Neighborhood status influences older women's cognitive function, study finds 2
... all those involved with healthcare decisions to ... latest evidence in their field of interest ... year as the volume of evidence increases. ... the best single source available for continually ...
... CVMstat® provides leading ... of topics involving all ... including sections on diagnosis ... arterial and venous disease. ...
... to the management of common ... a response from leading experts ... more common, and often poorly ... It is a "how-to" guide ...
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan...
Medicine Products: